Kezar Life Sciences, Inc. (KZR) Accumulated Expenses (2017 - 2026)

Kezar Life Sciences has reported Accumulated Expenses for 10 years, with the latest figure at $1.1 million in Q1 2026.

• Quarterly Accumulated Expenses fell 81.44% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 81.44% YoY) and the FY2025 annual result came in at $3.7 million, down 52.85% from the prior year.
• Accumulated Expenses eased to $1.1 million in Q1 2026 per KZR's latest filing, from $3.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $9.7 million in Q3 2024 and troughed at $42000.0 in Q3 2023.
• A 5-year average of $5.5 million and a median of $6.0 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 99.3% in 2023, then jumped 22909.52% in 2024.
• Over 5 years, Accumulated Expenses stood at $3.3 million in 2022, then jumped by 98.8% to $6.5 million in 2023, then rose by 22.43% to $7.9 million in 2024, then plunged by 52.85% to $3.7 million in 2025, then plunged by 69.66% to $1.1 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.1 million, $3.7 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.